Mayo Clinic LVAD Study Suggests Market Expansion

A recent Mayo Clinic study shows improved survival rates in patients with end-stage restrictive cardiomyopathy (RCM) who received left ventricular assist devices (LVADs). The potential to treat more heart failure patients could expand the market for LVADs, which currently are used in the treatment of other types of cardiomyopathy, either as a bridge to transplant (BTT), or as a destination therapy (DT).
Source: Medical Design Online News - Category: Medical Equipment Source Type: news